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1 | INTRODUCTION
Allergic rhinitis (AR) affects up to one-third of the adult population
and causes illness and disability world-wide.1 Main symptoms include
sneezing, rhinorrhea and nasal obstruction. AR is often accompanied
with conjunctivitis, characterized by watery, itchy and sometimes red
or swollen eyes. House dust mite (HDM) allergens are one of the
most relevant indoor allergy triggers.2 Treatment of AR consists of
symptomatic medications (mainly antihistamines and nasal corticos-
teroids) and allergen-specific immunotherapy (in more severe cases).1
Although HDM avoidance is generally recommended, there is little
evidence of beneficial effects on allergy symptoms. Several studies
evaluated the effect of HDM avoidance in patients with AR, how-
ever, to date only nine studies fulfil the criteria of randomized clini-
cal trials (RCTs).3 Five of these studies evaluated the use of
impermeable bedding covers, alone or in combination with other
avoidance measures. Based on these studies, especially the study by
Terreehorst et al.4, it is concluded that the isolated use of imperme-
able bedding is unlikely to be effective.3 The use of high efficiency
particulate air (HEPA) filters is poorly investigated (two small
studies), and results are not convincing.3 Two small RCTs in the early
1990s suggested some beneficial effects of acaricides as a HDM
avoidance measure, but to date, no larger, well-designed RCTs have
confirmed the results.3
As current evidence for existing HDM avoidance measures is low,
new methods are being developed. Purotex is a probiotics-based tex-
tile treatment, which contains five different probiotic and natural bac-
terial strains of Bacillus species (strains of Bacillus subtilis, Bacillus
amyloliquefaciens and Bacillus pumilus). In laboratory setting, Purotex-
treated fabric showed a reduction of 89.3% of Der p 1 levels compared
with untreated fabric (BMA-Labor GbR, Bochum, Germany). However,
up to now, the effect of these probiotics-impregnated covers had not
been tested in a clinical trial. Therefore, we set out to perform the first
pilot RCT to evaluate the effectiveness of Purotex covers to reduce
HDM allergen levels in bedding, and to improve allergy symptoms and
quality of life (QoL) of patients with AR to HDM.
2 | METHODS
All patients were recruited via the Department of Otorhinolaryngol-
ogy in Ghent University Hospital (Belgium). Prior to patient*Melissa Dullaers and Philippe Gevaert contributed equally.
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enrolment, the trial was registered at clinical.trials.gov (NCT0
1997606).
Patients aged 18-65 years were considered eligible if they had
a clinical history consistent with AR to HDM for at least 1 year, a
positive skin prick test to D.Pteronyssinus (D.pt), a positive nasal
allergen provocation test (NAPT) to HDM extract (Alyostal, Staller-
genes) and sIgE to D.pt of at least 0.7 kU/L (ImmunoCAP; Phadia,
Uppsala, Sweden) at screening. Moreover, subjects were random-
ized only when Der p 1 was detectable (≥0.488 ng/mL dust
extract, corresponding to ≥9.76 ng/g dust) in dust samples col-
lected from their mattress and/or pillow at screening. This trial was
designed as an explorative pilot study with an intended sample size
of 20 patients.
Purotex textile treatment contains five different probiotic and
natural (not genetically modified) bacterial strains of Bacillus species.
The probiotic spores are encapsulated in microcapsules (2-3 lm),
which are diffusely inserted in the textile. Upon friction forces
between the cover and the sleeper’s body, a small number of the
microcapsules rupture and release their probiotic bacteria.
The probiotics-impregnated covers and the untreated (placebo)
covers were indistinguishable from one another: they were identical
in colour, feeling and smell.
The study was designed as a pilot double-blind, randomized, pla-
cebo-controlled, crossover trial (see Figure S1). The study consisted
of four periods: (i) a run-in period of 4 weeks (without study cover),
(ii) a first study period of 8 weeks (with probiotics-impregnated cov-
ers, resp. placebo covers), (iii) a washout period of at least 4 weeks
(without study cover) and (iv) a second study period of 8 weeks (with
placebo covers, resp. probiotics-impregnated covers).
Der p 1 levels in mattress and pillow dust samples were the pri-
mary outcome measures. Dust samples were collected by the
patients every 2 weeks (day 0, 14, 28, 42, 56).
Symptoms, QoL and use of reliever medication were secondary
outcome measures. Questionnaires (Visual Analogue Scales, VAS5;
Rhinoconjunctivitis Quality of Life Questionnaire, RQLQ6; Nocturnal
Rhinoconjunctivitis Quality of Life Questionnaire, NRQLQ7) were
completed weekly.
Additional descriptions of the methods can be found in
Appendix S1.
3 | RESULTS
Of 34 screened subjects, 24 subjects met all inclusion and exclusion
criteria and were randomized. Four randomized subjects discontin-
ued the trial, and finally, 20 patients were retained for analysis (pa-
tient enrolment and dropout are summarized in Figure S2). Patient
characteristics at screening are shown in Table S1.
Der p 1 levels, symptom and QoL scores at baseline of the Puro-
tex period and the placebo period were comparable (see Table 1).
A significant and comparable decrease in Der p 1 levels was
observed with the placebo covers and the probiotics-impregnated
covers (both for mattress and pillow dust samples) (see Figure 1).
With the probiotics-impregnated covers, there was a significant
overall improvement compared to baseline of several symptoms and
QoL scores (see Figure 1 and Figure S3): VAS for subjective control
of AR symptoms (P=.001), VAS for global discomfort (P=.008), VAS
for nose symptoms (P<.001), VAS for eye symptoms (P=.03), RQLQ
total score (P=.01), RQLQ nose symptoms (P=.02), RQLQ eye symp-
toms (P=.02) and NRQLQ total score (P=.02). Improvement of symp-
toms and QoL with the probiotics-impregnated covers occurred
mainly during the second half of the study period (week 5-8). By
contrast, there was not any significant overall change from baseline
with the placebo covers. However, the differences in effect between
the probiotics-impregnated covers and placebo were not significant.
The only significant P-value (P=.048 for NRQLQ sleeptime) for differ-
ence in effect between both study covers was no longer significant
after correction for multiple comparisons (Benjamini-Hochberg
procedure).
TABLE 1 Outcomes: baseline levels
Purotex period
(n=20)
Placebo period
(n=20) P-value*
VAS for AR symptoms
control, score/100
51.8 (39.5-64.2) 50.8 (38.4-63.1) .86
VAS for global
discomfort,
score/100
52.8 (40.5-65.0) 53.0 (40.8-65.3) .97
VAS for nasal
symptoms,
score/100
42.8 (32.0-53.6) 40.8 (30.0-51.6) .67
VAS for eye
symptoms,
score/100
35.2 (24.2-46.2) 28.6 (17.6-39.5) .19
VAS for interference
with sleep, score/100
43.8 (31.0-56.6) 43.0 (30.1-55.8) .89
VAS for lower airway
symptoms, score/100
15.7 (8.2-23.2) 17.3 (9.8-24.8) .64
RQLQ total score,
score/6
2.3 (1.8-2.7) 2.3 (1.8-2.8) .88
RQLQ nose symptoms,
score/6
2.7 (2.0-3.3) 2.6 (2.0-3.2) .81
RQLQ eye symptoms,
score/6
2.0 (1.4-2.5) 1.7 (1.2-2.2) .37
NRQLQ total score,
score/6
2.2 (1.6-2.7) 2.2 (1.7-2.8) .77
NRQLQ sleep, score/6 2.0 (1.4-2.7) 2.0 (1.6-2.9) .50
NRQLQ sleeptime
symptoms, score/6
2.1 (1.5 -2.7) 2.0 (1.5-2.6) .73
Der p 1 in Mattress
dust samples, ng/g
336 (128-884) 386 (146-1016) .60
Der p 1 in Pillow
dust samples, ng/g
126 (48-332) 186 (70-496) .26
Variables are presented as means with 95% Confidence Intervals.
*P-value for difference between Purotex and Placebo period (analysed
with Mixed models).
AR, Allergic Rhinitis; NRQLQ, Nocturnal Rhinoconjunctivitis Quality of
Life Questionnaire; RQLQ, Rhinoconjunctivitis Quality of Life Question-
naire; VAS, Visual Analogue Scale.
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F IGURE 1 (A) Relative (%) change from baseline of Der p 1 concentration in mattress and pillow dust samples, illustrated with line charts
(error bars represent 95% CI). Mattress Der p 1: significant decrease with both the probiotics-impregnated covers (P=.02) and the placebo covers
(P=.003); no difference in effect between both study covers (P=.98). Pillow Der p 1: significant decrease with both the probiotics-impregnated
covers (P=.001) and the placebo covers (P=.007); no difference in effect between both study covers (P=.36). (B) Change from baseline of VAS
scores and QoL scores (RQLQ, NRQLQ), illustrated with line charts (error bars represent Standard Errors of the Mean). VAS for control of AR:
significant improvement with probiotics (P=.001) and not with placebo (P=.81); no significant difference in effect between both study covers
(P=.17). VAS for nose symptoms: significant improvement with probiotics (P<.001) and not with placebo (P=.36); no significant difference in effect
between both study covers (P=.09). RQLQ total score: significant improvement with probiotics (P=.01) and not with placebo (P=.32); no
significant difference in effect between both study covers (P=.33). NRQLQ total score: significant improvement with probiotics (P=.02) and not
with placebo (P=.30); no significant difference in effect between both study covers (P=.14).AR, Allergic Rhinitis; NRQLQ, Nocturnal
Rhinoconjunctivitis Quality of Life Questionnaire; RQLQ, Rhinoconjunctivitis Quality of Life Questionnaire; VAS, Visual Analogue Scale
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Only minor changes of medication intake were observed, and
changes compared to baseline were not significant in both study
periods (P=.83 for placebo; P=.45 for probiotics; P=.71 for difference
between both periods).
4 | DISCUSSION
We conducted the first pilot, double-blind, randomized, placebo-con-
trolled clinical trial to investigate the effect of probiotics-impreg-
nated covers on (i) HDM allergen levels in bedding, and (ii) allergy
symptoms and QoL of patients with AR to HDM.
Although no difference in effect was observed on Der p 1 levels
between the probiotics-impregnated covers and the placebo covers,
only the probiotics-impregnated covers were associated with a sig-
nificant improvement of symptoms and QoL compared to baseline.
This observation may raise the hypothesis that the potential
effect of the probiotics on symptoms and QoL may not be (solely)
attributable to an effect on HDM allergen levels in bedding, but may
be related to direct effects of the probiotics on the patient. Although
evidence is rather limited, some studies have suggested beneficial
effects of probiotics for treatment or prevention of atopic dermati-
tis8 and AR.9
However, in this trial, the measured Der p 1 levels were highly
variable (both between-subject and within-subject observations) and
may not always have reflected the real levels in bedding. Dust sam-
pling is known to be inherently variable,10 and additional variation in
this trial may have resulted from possible improper dust sampling by
the patient. It should be noted that the Der p 1 levels in this trial
were markedly lower than those previously reported, which may
explain some of the lack of effect seen in this study. In addition, the
Der p 1 levels measured in the pillow dust samples should be con-
sidered less reliable, as the pillow dust samples were often inade-
quate in mass (19% of samples weighed <10 mg, see Appendix S1).
At last, it should be emphasized that both the placebo and the probi-
otics-impregnated covers were new. Indeed, new bedding material
tends to show a lower HDM concentration, which may explain the
decrease in HDM allergen levels with both covers.
To our knowledge, this study is the first clinical trial to evaluate
any probiotics-based method aiming to reduce HDM allergen expo-
sure. Other studies have investigated the effect of physical (heating,
ventilation, freezing, washing, barrier methods, air filtration, vacuum-
ing and ionizers) and/or chemical (acaricides) methods.3 Terreehorst
et al.4 reported a significant reduction in HDM levels in bedding
with impermeable covers compared to non-impermeable covers.
Nevertheless, this large study did not reveal a clinical effect on rhini-
tis symptoms of the impermeable covers compared to the non-
impermeable covers (even not a trend).
In the study by Terreehorst et al.4, patients were encouraged to
carry out additional avoidance measures (including weekly washing
and cleaning of bedding in water at 60°C, and ventilating the homes
according to regular schedules). Hence, the observed improvement
of rhinitis symptoms in this study may be attributed to these
additional avoidance measures, irrespective of the use of imperme-
able or non-impermeable bedding covers.
In our study, no additional avoidance measures were applied.
Moreover, patients were urged to use their allergy medication not as
maintenance treatment, but only when needed. Hence, the observed
improvements of symptoms and QoL are unlikely to be attributable
to either additional environmental control measures or increased
intake of allergy medication.
The use of the bedding covers in our study was generally well tol-
erated, and no serious adverse events were considered related to
Purotex. Three subjects had an airway infection during the Purotex
period (see Appendix S1); however, it is not possible to speculate on
a possible relation with Purotex based on this small pilot study.
The small sample size of this pilot trial entails a restricted statisti-
cal power to show significant differences in effect between the pro-
biotics-impregnated covers and the placebo covers. A power analysis
(in Appendix S1) revealed that a potential future large-scale study
should include 262 patients to have 90% chance that the currently
observed effect of probiotics-impregnated covers on QoL (evaluated
with RQLQ total score) would be significant compared to the pla-
cebo covers. Other limitations of the current trial include the rather
short study period, the possibility of carry-over effects in this cross-
over design, the possible influence of seasonal fluctuations in HDM
exposure and the lack of control on dust sample collection.
In conclusion, even though the probiotics-impregnated covers
compared to untreated covers did not show an effect on the pri-
mary outcome measure Der p 1 levels, there was significant
improvement compared to baseline of several symptoms and
allergy-related quality-of-life scores (secondary outcomes) with the
probiotics-impregnated covers and not with the placebo covers.
Although the effects of probiotics-impregnated covers were not
significant compared to untreated covers in this pilot study, these
findings are promising and warrant further exploration in a future
large-scale clinical trial.
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